Louie Naumovski, MD, PhD

Dr. Naumovski, M.D., Ph.D., brings to I-Mab over 30 years of experience as a physician-scientist and senior leader in the biopharmaceutical industry. He has an extensive track record in the early clinical development of novel oncology drugs, including antibodies, antibody drug conjugates, novel biologics, and small molecules. Most recently, Dr. Naumovski served as Chief Medical Officer at Genesis Therapeutics and Arch Oncology. Prior to that, he was Group Medical Director of Oncology Early Development and a Volwiler Clinical Research Fellow at AbbVie. Prior to his role at AbbVie, Dr. Naumovski was a project team leader and an associate medical director of Exploratory Clinical Development at Genentech BioOncology. Previously, he was Director of Cancer Biology at Pharmacyclics. Earlier in his career, Dr. Naumovski served as an assistant professor of Pediatrics, Division of Hematology/Oncology/BMT at Stanford University School of Medicine. He holds an M.D. and a Ph.D. in Cancer Biology from Stanford University and a B.A. in Microbiology from the University of California-Los Angeles.